MRNA-based dendritic cell vaccines. (February 2014)

• Record Type: Journal Article
• Authors: Benteyn, Daphné; Heirman, Carlo; Bonehill, Aude; Thielemans, Kris; Breckpot, Karine
• Is Part Of: Expert review of vaccines. Volume 14:Number 2(2015)
• Page Start: 161
• Page End: 176
• Publication Date: 2014-02
• Subjects: Vaccines -- Periodicals; Vaccination -- Periodicals; 615.37205
• DOI: 10.1586/14760584.2014.957684
• Languages: English
• ISSNs: 1476-0584

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>Cancer immunotherapy has been proposed as a powerful treatment modality. Active immunotherapy aspires to stimulate the patient's immune system, particularly T cells. These cells can recognize and kill cancer cells and can form an immunological memory. Dendritic cells (DCs) are the professional antigen-presenting cells of our immune system. They take up and process antigens to present them to T cells. Consequently, DCs have been investigated as a means to stimulate cancer-specific T-cell responses. An efficient strategy to program DCs is the use of mRNA, a well-defined and safe molecule that can be easily generated at high purity. Importantly, vaccines consisting of mRNA-modified DCs showed promising results in clinical trials. Therefore, we will introduce cancer immunotherapy and DCs and give a detailed overview on the application of mRNA to generate cancer-fighting DC vaccines.</p> </abstract>